EUCTR2021-000184-78-DK进行中（未招募）1 期
Recurrent and Metastatic Prostate Cancer: Impact of 18F-PSMA-1007 PET/CT on clinical decision making and response monitoring - RE-PRISMA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Has given informed consent to participate
- •Minimum age 18 years
- •Can understand provided patient information material in Danish
- •Verified metastatic castration resistant prostate cancer both clinically and by imaging, all degrees of dissemination included
- •Life expectancy more than 3 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •Serious medical conditions preventing treatment for prostate cancer
- •Psychiatric diagnosis, or other circumstances where the will or ability to perform the planned imaging and investigations is questionable
- •Known allergy for the PSMA tracer or other contents in the solution
研究者
相似试验
招募中
2 期
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trial2024-513207-13-00Institut De Cancerologie De L Ouest96
已完成
1 期
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Cancer - ProstateProstate CancerACTRN12615000912583Peter MacCallum Cancer Centre30
招募中
不适用
Prostate Cancer Outcomes – Compare & Reduce Variation in Prostate Cancer Centers certified by the German Cancer Society; subproject MID-EPIC-DDRKS00010774Deutsche Krebsgesellschaft70,000
尚未招募
不适用
Impact of local therapy for metastatic prostate cancermetastatic prostate cancerJPRN-UMIN000034795Hirosaki University School of Medicine50
Unknown
3 期
Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14Prostatic NeoplasmsNCT03119857Göteborg University349